It was also observed that the presence of the mutated form of this oncogene is associated with lower TIL (tumor infiltrating lymphocytes), while inhibition of BRAF or MEK results in an increased number of melanocyte antigens on melanoma cells (e.g., MART-1, gp-100) and their enhanced recognition by lymphocytes [87]. This evidence concerns the gene BRAF and melanoma.